TRCT
ARGS

Tower Research Capital (TRC)’s Argos Therapeutics, Inc. ARGS Stock Holding History

Tower Research Capital (TRC)’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-246
Closed -$2K – 4491
2017
Q2 		$2K Sell
246
-111
-31% -$945 ﹤0.01% 2444
2017
Q1 		$3K Buy
357
+342
+2,280% +$21.6K ﹤0.01% 2570
2016
Q4 		$1K Buy
+15
New +$1.4K ﹤0.01% 3760
2016
Q3 		– Sell
-10
Closed -$1K – 5296
2016
Q2 		$1K Sell
10
-81
-89% -$10.8K ﹤0.01% 4359
2016
Q1 		$11K Buy
+91
New +$7.36K ﹤0.01% 1924
2015
Q4 		– Sell
-240
Closed -$23K – 5761
2015
Q3 		$23K Buy
240
+238
+11,900% +$28.2K ﹤0.01% 1633
2015
Q2 		$0 Sell
2
-4
-67% -$639 ﹤0.01% 5738
2015
Q1 		$1K Hold
6
– – ﹤0.01% 4330
2014
Q4 		$1K Sell
6
-73
-92% -$13.1K ﹤0.01% 3908
2014
Q3 		$16K Buy
79
+66
+508% +$10.3K ﹤0.01% 2526
2014
Q2 		$2K Sell
13
-81
-86% -$13.4K ﹤0.01% 3592
2014
Q1 		$19K Buy
+94
New +$18.8K ﹤0.01% 1976

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
KeyBank National Association
KeyBank National Association Cleveland, Ohio $30.4B AUM 27.51% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Tower Research Capital (TRC)'s ARGS Position: Q3 2017 in Review

Tower Research Capital (TRC) sold out of Argos Therapeutics, Inc. (ARGS) in Q3 2017, closing a stake of 246 shares — an estimated $2K sold.

Tower Research Capital (TRC) first reported a position in ARGS in Q1 2014 and held it in 12 quarters. The position peaked at $23K in Q3 2015. 29 funds tracked by Wall St. Rank hold ARGS as of Q3 2017.

  • Tower Research Capital (TRC) reported no remaining Argos Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 246 Argos Therapeutics, Inc. shares in Q3 2017, an estimated $2K.
  • Tower Research Capital (TRC) first reported a position in Argos Therapeutics, Inc. in Q1 2014 and held it in 12 quarters.
  • Tower Research Capital (TRC)'s Argos Therapeutics, Inc. position peaked at $23K in Q3 2015.
  • 29 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q3 2017.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2017, filed 14 Nov 2017.